ALEXANDRIA, Va. — The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan (Enhertu®) can help people with advanced HER2-positive gastric ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive ... DS-3939, a TA-MUC1 directed ADC, is being developed ...

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 ... DS-3939, a TA-MUC1 directed ADC, is being developed ...

Enhertu plus Perjeta improved median PFS to 40.7 months versus 26.9 months with standard care in HER2-positive breast cancer. The PFS benefit was consistent across subgroups, including hormone ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--ENHERTU plus Pertuzumab Reduced Risk of Disease Progression or Death by 44% vs. THP as 1L Therapy in Patients w/ HER2 positive mBC in DESTINY-Breast09 ...

TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...

Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds. Findings on AstraZeneca, Daiichi Sankyo drug could set a new standard of care.

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 ...

- A recent Phase III trial, DESTINY-Breast09, has demonstrated a significant improvement in progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer treated with ...

MONDAY, Feb. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic ...